RSV vaccine sales for elderly to top $10B by 2030 in G7 (NYSE:PFE)

Ahead of the world’s first immunization drive against respiratory syncytial virus (RSV), a new report from the London-based health analytics firm Airfinity suggests RSV vaccine sales for older adults could exceed $10B by 2030 in G7 countries.

For years, RSV was an unmet medical need until GSK (NYSE:GSK) and Pfizer (NYSE:PFE) developed vaccines against the virus. RSV infects the lungs and respiratory tract, causing about 60–160K hospitalizations and 6K–10K deaths among older adults in the U.S. annually.